双鹭药业(002038) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was ¥146,187,751.94, a decrease of 19.58% year-on-year[8]. - Operating revenue for the period was ¥525,545,782.01, down 7.85% compared to the same period last year[8]. - The net profit after deducting non-recurring gains and losses was ¥129,684,786.01, a decrease of 29.99% year-on-year[8]. - Basic earnings per share were ¥0.1423, reflecting a decline of 19.56% compared to the previous year[8]. - The company reported a total comprehensive income of ¥132,695,982.83, down from ¥183,179,715.80 in the previous period[59]. - Net profit for the current period is ¥144,566,951.24, down 19.9% from ¥180,550,477.12 in the previous period[55]. - The company reported a total comprehensive income of ¥486,927,957.80, down from ¥528,484,040.23 in the previous period[75]. - Net profit fell to ¥476,335,490.24 from ¥816,864,176.02, a decrease of 41.7%[78]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥5,248,931,879.02, an increase of 5.23% compared to the previous year[8]. - Total current assets reached ¥3,028,426,912.70 as of September 30, 2019, compared to ¥2,803,158,056.97 at the end of 2018[35]. - Total liabilities decreased from 469,731,768.57 to 448,931,296.65, a reduction of approximately 4.3%[38]. - Current liabilities decreased from 440,524,918.48 to 419,724,446.56, a decline of about 4.7%[38]. - Total equity increased from 4,518,542,624.57 to 4,800,000,582.37, representing a growth of approximately 6.2%[41]. - Total assets rose from 4,922,888,869.61 to 5,176,207,481.99, an increase of about 5.2%[45]. - The company’s total liabilities were recorded at ¥440,524,918.48, reflecting its financial obligations[105]. Cash Flow - The net cash flow from operating activities was ¥113,325,428.62, a decrease of 20.25% year-on-year[8]. - Cash flow from operating activities increased to ¥462,953,174.97 compared to ¥377,896,165.50, an increase of 22.4%[89]. - Net cash flow from operating activities increased to ¥424,192,129.99, up from ¥377,049,190.70, representing a growth of approximately 12.4% year-over-year[95]. - Net cash flow from financing activities was -¥205,470,000.00, compared to -¥342,450,000.00, indicating an improvement of approximately 40%[98]. Research and Development - R&D expenses grew by 58.19% year-on-year, reflecting increased investment in research and related intermediate trials and material consumption[19]. - Research and development expenses rose significantly to ¥36,602,802.69, an increase of 98.1% compared to ¥18,470,836.24 in the previous period[52]. - R&D expenses increased to ¥88,589,486.44 from ¥52,362,760.31, representing a growth of 68.9% year-over-year[78]. - The company plans to continue focusing on R&D and market expansion strategies to drive future growth[58]. Shareholder Information - The top two shareholders, Xu Mingbo and Xinxiang Bailu Investment Group, hold 22.58% and 20.63% of shares respectively[12]. - The company did not engage in any repurchase agreements during the reporting period[16]. - The company has no overdue commitments from major shareholders or related parties during the reporting period[20]. Other Income and Expenses - Other income surged by 1516.83% year-on-year, mainly due to increased government subsidies from national science and technology programs and local innovation initiatives[19]. - Other income increased to ¥12,215,000.00 from ¥150,000.00 in the previous period, indicating a substantial growth[52]. - Other income surged to ¥24,487,311.05 from ¥2,926,895.13, marking an increase of 736.5%[78]. - Tax expenses decreased to ¥17,373,374.85 from ¥21,888,283.90, a reduction of 20.5%[55].